Table 2.
Choice of guideline drugs for uncomplicated urinary tract infection in 2017 stratified for age category
| Age category | 18–30 | 31–40 | 41–50 | 51–60 | 61–70 | 71–80 | >80 |
|---|---|---|---|---|---|---|---|
| Usersa of: | |||||||
| at least one uncomplicated UTI antibiotic (=n) | 142,771b | 89,001 | 96,547 | 116,924 | 123,627 | 114,818 | 103,525 |
| nitrofurantoin (% of n) | 129,933 (91.0%) | 80,147 (90.1%) | 84,504 (78.4%) | 99,740 (85.3%) | 102,362 (82.8%) | 91,653 (79.8%) | 76,393 (73.8%) |
| fosfomycin (% of n) | 17,880 (12.5%) | 11,782 (13.2%) | 16,460 (15.3%) | 23,729 (20.3%) | 29,954 (24.4%) | 33,687 (29.3%) | 37,948 (36.7%) |
| trimethoprim (% of n) | 6873 (4.8%) | 5044 (5.7%) | 6798 (6.3%) | 9467 (8.1%) | 12,323 (10.0%) | 13,852 (12.1%) | 15,409 (14.9%) |
| Startersc of: | |||||||
| at least one uncomplicated UTI antibiotic (=n) | 120,901b | 75,120 | 79,312 | 93,305 | 95,309 | 85,457 | 74,984 |
| nitrofurantoin (% of n) | 107,843 (89.2%) | 66,102 (88.0%) | 67,562 (85.2%) | 76,841 (82.4%) | 75,077 (78.8%) | 63,163 (73.9%) | 49,776 (66.4%) |
| fosfomycin (% of n) | 15,403 (12.7%) | 10,139 (13.5%) | 13,641 (17.2%) | 19,012 (20.4%) | 23,059 (24.2%) | 24,925 (29.2%) | 27,125 (36.2%) |
| trimethoprim (% of n) | 5888 (4.9%) | 4199 (5.6%) | 5415 (6.8%) | 7414 (7.9%) | 9314 (9.8%) | 10,031 (11.7%) | 10,834 (14.4%) |
| Usersa of: | |||||||
| at least one febrile UTI antibiotic within 14 days (% of n) | 3586 (2.5%)b | 2747 (3.1%) | 3559 (3.7%) | 5382 (4.6%) | 7128 (5.8%) | 8480 (7.4%) | 10,806 (10.4%) |
| ciprofloxacin (% of n) | 2026 (1.4%) | 1509 (1.7%) | 2277 (2.4%) | 3497 (3.0%) | 4460 (3.8%) | 5502 (4.8%) | 6817 (6.6%) |
| amoxicillin/clavulanic acid (% of n) | 1448 (1.0%) | 1110 (1.2%) | 1075 (1.1%) | 1596 (1.4%) | 2168 (1.8%) | 2714 (2.4%) | 3976 (3.8%) |
| co-trimoxazole (% of n) | 242 (0.2%) | 211 (0.2%) | 339 (0.4%) | 515 (0.4%) | 645 (0.5%) | 810 (0.7%) | 888 (0.9%) |
a
The number of users was extrapolated to the number of all community pharmacies in the Netherlands in 2017; in 2017, data were available from 1765 community pharmacies (89% of all community pharmacies).
b
The sum of users of all guideline drugs per year is higher than 100% due to patients with more than one type of guideline drug per year.
c
No dispensing of the same drug within the preceding 12 months.